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SPSS by bivariate analyses with two-sided Chi-square test. In the next step the
subgroups of patients with comparable treatment in clinical practice were defined
and analysed in a multivariate analysis. RESULTS: By contrast to the recommen-
dation of national guidelines, intensified therapy was administered less frequently
in patients with the aim of “resection of metastases” (43%), whereas the highest use
(64%) was reported in “patients with tumor related symptoms or at risk for rapid
progression or deterioration”. This group represents only 12% of the 1st line. Fac-
tors with an influence on the use of intensified therapy in daily practice were
analyzed in a multivariate analysis. Three treatment clusters (comprising 89% of
patient sample) were determined. (all p0,05) The cluster with significantly higher
use of intensified therapy (18% above mean value of 54%) is distinguished by: Age
70 y., better PS (80% KI), no symptoms and/or without concomitant diseases,
treatment in office based setting. Patients in this cluster show less tumor
dynamics. CONCLUSIONS: In daily practice, the application of the decision model
based on treatment aims for clinical subgroups is not generally used. Intensified
treatment is more likely associated with individual patient characteristics and
institutional framework. This, however, underlines the need for a critical discus-
sion of the currently suggested decision-making models.
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OBJECTIVES: Reimbursement agencies require estimates of the long-term (i.e. life-
time) costs and benefits associated with each treatment option as part of the deci-
sion making process. As such, extrapolation of reported survival estimates is inev-
itable. Conventionally, information on all-cause mortality or disease progression is
used. However, data for newly diagnosed CML may not be suited to such an extrap-
olation due to the paucity of observed events. One of solutions is to use a ‘surrogate
approach’.METHODS: A 40 year Excel® based model was created to estimate over-
all (OS) and progression-free (PFS) survival in newly diagnosed CML patients re-
ceiving 1st or 2nd generation tyrosine kinease inhibitor (TKI) therapy through the
use of a surrogate clinical endpoint (cytogenic response - CyR). Three response
categories (complete, partial or no CyR at one year) were used. Long term response
category specific OS and PFS data from IRIS clinical trial was used to inform the
fitting of Weibull functions with goodness of fit assessed via the R2 statistic. CyR
response rates were taken from a recently published network meta-analysis of
first-line interventions. RESULTS: Using the conventional approach, CML patients
were predicted to have an equivalent survival profile to the non-CML general pop-
ulation (31.6 versus 32.6 years), and the survival difference between 1st and 2nd
generation drugs are 9 years (31.6 versus 22.8 years) (Botteman et al 2010). However,
predicted OS estimates for 1st and 2nd generation TKI’s using the surrogate ap-
proach are 18.6 and 20.1 years respectively (R2 values 0.97, 0.94). Compared to 1st
generation drugs the use of 2nd generation TKI’s results in approximately 1.5 ad-
ditional years of survival. CONCLUSIONS: Extrapolating short term overall OS data
in newly diagnosed CML results in inflated survival estimates. When a valid clinical
surrogate is used there is a much smaller, and believable, difference in the pre-
dicted survival values.
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OBJECTIVES: Progression-free survival (PFS) is frequently used to establish the
clinical efficacy of anti-cancer drugs. However, this surrogate measure of survival
is of limited interest for the economic evaluation of these treatments. Therefore,
the aim of this study is to develop a predictive model for OS based on PFS data in the
context of metastatic breast cancer (mBC), which would be suitable for cost-effec-
tiveness (cost per life-year saved) and cost-utility analyses. METHODS: A system-
atic review of the literature was conducted according to the PICO method: Popula-
tion consisted of women with mBC; Interventions and Comparators were standard
treatments for mBC or best supportive care; Outcomes of interest were median PFS
and median OS. All selected studies were randomized trials published from 1990 to
2010. Two independent reviewers screened titles, abstracts, and full papers for
eligibility. Then, reviewers independently extracted data from selected studies
(median PFS, median OS, and potentially predictive covariates). The relationship
between PFS and OS was assessed by calculating Pearson’s correlation coefficient.
Finally, statistical analyses (ANOVA and Pearson’s correlation) were performed to
identify covariates having a significant impact on OS. RESULTS: A total of 5041
studies were identified and 151 fulfilled the eligibility criteria. According to the data
extracted from selected studies, there is a significant relationship between median
PFS and median OS (r0.373;p0.01). Moreover, many covariates have a statisti-
cally significant impact on OS including age (p0.01), type of treatment (p0.01),
line of treatment (p0.01), ECOG status (p0.01), and number and sites of metas-
tasis (p0.01). CONCLUSIONS: Results of this systematic review point toward a
significant relationship between PFS and OS in the context of mBC. These findings
will enable the development of a predictive model for OS based on PFS and signif-
icant covariates, which will eventually bring answers to an important challenge in
the economic evaluation of anti-cancer drugs.
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OBJECTIVES: To compare the costs of XELOX (Xeloda  Oxaliplatin) and FOLFOX4
(5-FU  Oxaliplatin  Leucovorin) for adjuvant treatment of stage III colon cancer
in a South Korean setting. METHODS: Based on the equivalence in efficacy of
XELOX from NO16968 trial and FOLFOX4 from MOSAIC trial (the 5 yrs disease free
survival rates were very similar 66.1% for XELOX and 66.4% for FOLFOX4), a cost-
minimization approach was chosen. The model adopts a payers perspective. Effi-
cacy/Safety data and protocol information were acquired from NO16968 for XELOX,
and from the MOSAIC trial for FOLFOX4. As no direct comparison of XELOX and
FOLFOX4 for this indication is available, we collected several medical resource use
data for these two regimens, which were chemotherapy drug doses, adverse
events, hospitalization-ambulatory visits, and drug administration methods. The
medical costs for FOLFOX4 were acquired from real world claims data (electronic
data interchange, EDI); Catholic medical center in Korea. The direct medical costs
for XELOX were also estimated by EDI from Catholic medical center with NO16968
trial. Also, health care utilizations were measured. All data analyses were per-
formed using STATA software. RESULTS: The total direct medical costs for XELOX
were estimated to be 13,884,894 KRW and for FOLFOX4 14,509,341 KRW per patient
for 24weeks of chemotherapy treatment at same body surface area. The drug costs
of XELOX were 12,468,748 KRW and of FOLFOX4 10,831,699 KRW. The line costs and
drug administration costs were 82,960 KRW for XELOX and, 943,176 KRW for FOL-
FOX4, respectively. XELOX is more expensive in terms of drug acquisition costs.
However, this is more than compensated by cost savings for drug administration,
ambulatory encounters, AE medications, costs for central venous lines, and hospi-
talization. Additional incidence of hospitalization for FOLFOX4 was 2.3 times
greater than for XELOX related hospitalization. CONCLUSIONS: XELOX offers cost
savings of 644,447 KRW (about 585 US $) per patient compared to FOLFOX4 from the
payers perspective in South Korean Universal Health Insurance System.
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OBJECTIVES: In order for a new therapy to be included and reimbursed on the basic
list of treatments covered by Croatian Institute for Health Insurance (HZZO), it
must prove to have a positive effect on the budget impact analysis (BIA). The
standard therapy for patients suffering from advanced head and neck cancer is
chemoradiotherapy (mainly platinum and radiotherapy). However, if chemother-
apy proves to be contraindicative, only radiotherapy is applied. Cetuximab inhibits
EGFR, which induces the apoptosis of cancer cells. It has been proven that the
implementation of immunoradiotherapy contributes to the overall survival of
patients. METHODS: Known costs of the standard therapy for advanced head and
neck cancer were compared with the costs of the proposed new therapy (cetux-
imab radiotherapy). The costs are shown in the croatian currency (HRK) (1 Euro
7,4 HRK). The increased costs of immunotherapy are compared to the data on
efficiency from published literature. RESULTS: Approximately 212 patients with
advanced head and neck cancer receive treatment in Croatia every year. If chemo-
therapy is contraindicative, a standard radiotherapy is applied (42 patients). The
HZZO spends yearly 840.000,00 HRK on the treatment of those patients. The inclu-
sion of cetuximab into the standard therapy would increase the total yearly costs
by 3,082.650,90 HRK. When compared to radiatiotherapy, immunoradiotherapy
prolongs the control of the illness (14,9 vs. 24,4 months), and the overall survival of
patients (29,3 vs. 49,0 months). The cost for one added life-year per patient, would
be approximately 89.738,00 HRK. CONCLUSIONS: The inclusion of immunotherapy
into the standard treatment of patients with advanced head and neck cancer would
have a negative impact on the budget of the HZZO. The average costs for one added
life-year are lower than the average costs of chronic kidney insufficiency patients.
PCN193
USING WHOLE DISEASE MODELLING TO INFORM ECONOMIC
RECOMMENDATIONS FOR THE DETECTION, DIAGNOSIS, TREATMENT AND
FOLLOW-UP OF COLORECTAL CANCER
Tappenden P, Brennan A, Chilcott J, Squires H
University of Sheffield, Sheffield, South Yorkshire, UK
OBJECTIVES: Conventional economic evaluation typically involves piecewise com-
parisons of competing technologies at a single isolated point in a broader care
pathway. This study assesses the value of simulating whole disease and treatment
pathways to provide a common economic basis for informing resource allocation
decisions across an entire disease service. This Whole Disease Modelling ap-
proach was applied to the evaluation of technologies for the detection, diagnosis,
treatment and follow-up of colorectal cancer. METHODS: A patient-level simula-
tion model was developed with the intention of informing NICE’s colorectal cancer
clinical guideline. The model simulates disease and treatment pathways from pre-
clinical disease through to detection, diagnosis, adjuvant treatment, follow-up,
treatments for metastases and supportive care. The model was populated using
randomised trials, observational studies, health utility studies, costing sources and
expert opinion. Unobservable natural history parameters were calibrated against
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